血栓友爱对静脉血栓塞栓症管理的影响
Joseph Emmerich1, Stéphane Zuily2, Isabelle Gouin-Thibault3
1Department of Vascular Medicine, Paris Saint-Joseph Hospital Group, University of Paris, 75014 Paris, France; INSERM CRESS UMR 1153, F-75005 Paris, France; FCRIN INNOVTE network, Saint-Etienne, France.
概括
高凝血状态,或血栓性,包括遗传和获得的条件. 虽然常见的突变对治疗的影响有限,但罕见的遗传血栓症和抗脂综合征显著影响患者管理和抗凝策略.
科学领域:
- 血液学 血液学 血液学
- 内部医学 内部医学
- 遗传学 遗传学 是一个
背景情况:
- 高凝血状态,或血栓性,包括遗传和获得的条件.
- 遗传性血栓形成症通常与凝血抑制剂缺乏或特定基因突变有关.
- 获得的血栓ophilia,特别是抗脂综合征 (APS),与动脉和静脉血栓形成有关.
研究的目的:
- 审查各种类型的血栓友爱症的临床意义.
- 讨论血栓友爱对血栓形成的管理的影响.
- 为了突出基于血栓友爱症分类的治疗决策的差异.
主要方法:
- 关于先天性和获得性血栓友的文献综述.
- 对常见和罕见的血栓友突变的临床影响的分析.
- 对血栓形成症的管理策略的评估,包括抗凝血和预防.
主要成果:
- 常见的遗传性血栓性突变 (V Leiden因子,前列血G20210A) 对静脉血栓复发的影响有限.
- 罕见的遗传性血栓症,如抗血栓素缺乏症,可能需要长期使用抗凝药.
- 抗脂综合征显著影响管理,影响抗凝剂的选择,持续时间和免疫抑制的需要.
结论:
- 血栓过敏症的分类对于指导血栓的管理至关重要.
- 虽然常见的突变的影响很小,但罕见的遗传形式和APS需要量身定制的治疗方法.
- 抗脂综合征需要除了抗凝药外的综合管理,包括监测器官参与和自身免疫性疾病.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis
754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Return
3.4K
The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
3.4K
Clot Retraction and Fibrinolysis
4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499


